Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.44 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL928538 | 0.86 | PTGS1 (0.54) | KMT2AMEN1GAAPTGS1IP6K1 | |
| SCHEMBL4676416 | 0.85 | PTGS1 (0.53) | KMT2AMEN1GAAPTGS1PTPN1 | |
| Hydrochloric Acid SCHEMBL19119250 | 0.85 | PTGS1 (0.53) | KMT2AMEN1GAAPTGS1IP6K1 | |
| SCHEMBL13508 | 0.83 | PTGS1 (0.51) | KMT2AMEN1GAAPTGS1IP6K1 | |
| SCHEMBL6710243 | 0.83 | PTGS1 (0.51) | KMT2AMEN1GAAPTGS1IP6K1 | |
| SCHEMBL893014 | 0.83 | PTGS1 (0.51) | KMT2AMEN1GAAPTGS1IP6K1 | |
| SCHEMBL11128848 | 0.83 | PTGS1 (0.51) | KMT2AMEN1GAAPTGS1IP6K1 | |
| SCHEMBL16502243 | 0.81 | PTGS1 (0.73) | KMT2AMEN1PTGS1PTPN1MAPT | |
| SCHEMBL353820 | 0.81 | IP6K1 (0.53) | KMT2AMEN1GAAPTGS1IP6K1 | |
| SCHEMBL13438 | 0.78 | PTGS1 (0.69) | KMT2AMEN1PTGS1MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| CN-100384418-C | Isoxazolopyridinones and use thereof in the treatment of parkinson's disease | NOVARTIS AG (CH) | 2008-04-30 | — | — | CN | disclosed |
| EP-1418912-B1 | ISOXAZOLOPYRIDINONES | NOVARTIS AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-7087756-B2 | Isoxazolopyridinones | NOVARTIS AG (CH) | 2006-08-08 | — | — | US | disclosed |
| CN-1635889-A | Isoxazolopyridinones and their use in the treatment of parkinson's disease | NOVARTIS AG (CH) | 2005-07-06 | — | — | CN | disclosed |
| US-20040248893-A1 | Isoxazolopyridinones | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1418912-A2 | ISOXAZOLOPYRIDINONES | Novartis AG (CH) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003015780-A2 | ISOXAZOLOPYRIDINONES AND USE THEREOF IN THE TREATMENT OF PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248893-A1 | Isoxazolopyridinones | XDH, NPY1R, TBXA2R | KMT2A 2514/4885MEN1 1279/4885GAA 2766/4885 |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | KMT2A 3181/4885MEN1 4100/4885GAA 111/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | KMT2A 2853/4885MEN1 4132/4885GAA 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.